Reference
1. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45822
2. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45805&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2
3. 엄태선 기자. ” 차세대 의료제품 평가기반 등 17과제 ..내년15억원 투입뉴스더보이스헬스케어(2021.10.28)
Available from: https://www.newsthevoice.com/news/articleView.html?idxno=15576
4. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45880
5. 이현주 기자. "1조 신약개발사 육성·희귀질환 치료기술 개발·의료기기 전주기 지원" 히트뉴스(2021.10.07.)
Available from: http://www.hitnews.co.kr/news/articleView.html?idxno=36267
6.보건복지부 홈페이지 Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=368174
7.이승덕 기자. “범부처재생의료사업단-바이오의약품협회, 연구개발 MOU 체결“ 의학신문(2021.10.19)
Available from: http://www.bosa.co.kr/news/articleView.html?idxno=2160491
8. “Approval Letter-TECARTUS” US FDA., Last modified Oct 1. 2021, Accessed Oct 1. 2021, Available from: https://www.fda.gov/media/152696/download
9.“FDA Approvals Roundup:Livmarli and Tecartus” Regulatory Focus. Last modified Oct 6. 2021, Accessed Oct 8. 2021, Available from: https://www.raps.org/news-and-articles/news-articles/2021/10/fda-approvals-roundup-livmarli
10. “FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia” US FDA. Last modified Oct 8. 2021, Accessed Oct 8. 2021, Available from: .https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-treatment-pediatric-patients-congenital-athymia
11. “Approval Letter-RETHYMIIC” US FDA., Last modified Oct 8. 2021, Accessed Oct 9. 2021, Available from: https://www.fda.gov/media/152935/download
12. “Approval Letter-ZOLGENSMA” US FDA., Last modified Oct 26. 2021, Accessed Oct 26. 2021, Available from: https://www.fda.gov/media/153524/download?utm_medium=email&utm_source=govdelivery
13. “FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases” US FDA, Last modified Oct 27. 2021, Accessed Oct 28. 2021, Available from: https://www.fda.gov/news-events/press-announcements/fda-nih-and-15-private-organizations-join-forces-increase-effective-gene-therapies-rare-diseases
14. “What’s new” EMA. Last modified Oct 19. 2021, Accessed Oct 20. 2021
Available from: https://www.ema.europa.eu/documents/report/list-products-granted-eligibility-prime_en-0.xlsx
15. “Committee for Advanced Therapies (CAT): work-plan-Oct” EMA. Last modified Oct 8.
2021, Accessed Oct 10. 2021
Available from: https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-6-8-october-2021-meeting_en.pdf
16. “Orphan designations-eu3151499” EMA. Last modified Oct 13. 2021, Accessed Oct. 17. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1499
17. “Orphan designations-eu3171852” EMA. Last modified Oct 13. 2021, Accessed Oct. 17. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1852
18. “Zynteglo” EMA. Last modified Oct 4. 2021, Accessed Oct. 19, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo
19. “Kymriah” EMA. Last modified Oct 11. 2021, Accessed Oct. 19, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah
20. “Tecartus” EMA. Last modified Oct 15. 2021, Accessed Oct. 20, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus
21. “Abecma” EMA. Last modified Oct 28. 2021, Accessed Oct. 29, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abecma
22. “Imlygic” EMA. Last modified Oct 26. 2021, Accessed Oct. 29, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic
23. 일본외무성 홈페이지 Available from: https://www.mofa.go.jp/mofaj/press/release/press4_009154.html
24.日 게이오대 연구진, 유도만능줄기세포 (iPS) 이용한 척수손상치료에서 새로운 재생의료 치료법 개발(21.10.15)
Available from: https://www.keio.ac.jp/ja/press-releases/2021/10/15/28-83169/
25.사카 시립대학, 플라즈마 이용한 뼈 재생을 촉진하는 효율적인 재생의료 치료 개발(21.10.22)
Available from: https://news.yahoo.co.jp/articles/85f6376d742a942433dcea50241cee118ffab778
26.노신영 기자. “다케다, 셀렉타 '면역관용 AAV 플랫폼' 11.24억弗 딜“ (2021.10.06.) 바이오스펙테이더
Available from: http://www.biospectator.com/view/news_view.php?varAtcId=14317
27. 김성민 기자. 다케다, "1억弗 투자" γδ T세포 파트너사 "아예" 인수 바이오스펙데이터(2021.10.29.)
Available from: http://www.biospectator.com/view/news_view.php?varAtcId=14501
28. 의약품안전나라 의약품통합정보시스템 홈페이지
Available from: https://nedrug.mfds.go.kr/index
29.이상수 기자“ 전세계 신속 인허가 검토 경로(expedited regulatory review pathways)의 기회와 요건”(2018.09.27.)의료기기뉴스라인
Available from: http://www.kmdianews.com/news/articleView.html?idxno=26451
30. 조양래 기자 “미국 FDA 신약심사와 관련된 특별한 제도: 혁신신약, 가속허가, 우선심사”메디게이트 (2001.01.06.)
Available from: https://m.medigatenews.com/news/1928386217
31.최윤수 기자 “해외 주요국 신속심사·신청방법① - FDA편” 약업뉴스(2021.10.25.)
Available from: https://www.yakup.com/news/index.html?mode=view&nid=262245
32.일본에서의 경험: 조건부 및 시간 제한 승인 – 재생 의료 제품에 대한 조기 승인 제도(2019.06.24.)
Available from: https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/179/Experiences-from-Japan-conditional-and-time-limited-approval-an-early-approval-scheme-for-regenerative-medical-products
33.유럽의약품기구 홈페이지
Available from: www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring
34. 일본의약품의료기기청 홈페이지
Available from: https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html
35.유럽의약품기구 홈페이지
Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring
36.박숙현 기자 식약처, “인보사케이주 투여환자에 15년 장기추적조사 실시…국민에 심려끼쳐 죄송하다”(2019.06.05.)민족의학신문
Available from: http://www.mjmedi.com/news/articleView.html?idxno=36822
37.식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_1060/view.do?seq=14913
38.김영주 기자 “파이프라인으로 본 국내 신약개발 양적·질적 성장 ‘뚜렷’”(2021.09.06.)의학신문
Available from: http://www.bosa.co.kr/news/articleView.html?idxno=2157764
39.환경오피니언스 사설“첨단 유전자기술, 미국서 실험하고 일본서 허가받는 현실”(2017.08.04.)
Available from: https://www.hankyung.com/opinion/article/2017080342281
40.식품의약품안전평가원 홈페이지
Available from: https://www.nifds.go.kr/brd/m_137/list.do
41.식품의약품안전평가원 홈페이지
Available from: http://www.nifds.go.kr/brd/m_137/view.do?seq=32874&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
42.식품의약품안전처 홈페이지
Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=44418&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
43.한국보건산업진흥원 김용민;홍영주;김수경 바이오의약품 산업 분석 및 정책 연구 (2021.03.30)
Available from: https://www.khidi.or.kr/board/view?pageNum=1&rowCnt=10&no1=1&linkId=48854617&menuId=MENU02686&maxIndex=00488546179998&minIndex=00488546179998&schType=0&schText=&schStartDate=&schEndDate=&boardStyle=&categoryId=&continent=&country=